Traders should monitor APOLLO Phase 3 top-line results in Q4 2026 as the single most important binary catalyst, success would confirm the CRL-response path and likely drive a >8-15% rally for this early-stage biotech. The RALLY-MF data strengthen the DISC-0974 profile ahead of End-of-Phase 2 meetings, supporting a second pivotal program. DISC-3405 initial data in Q4 adds further optionality.
IRON drugs
IRON drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 12 $67.99entry
- T+1 · 5mo ago +3.09%α +1.33% · $70.09
- T+5 · 5mo ago +4.12%α +3.45% · $70.79
- T+20 · 4mo ago +12.65%α +10.87% · $76.59
- T+60 · 2mo ago +13.02%α +9.75% · $76.84
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Disc Medicine announced updated Phase 2 data for DISC-0974 in myelofibrosis anemia (55% major response in non-transfusion-dependent patients, 64% transfusion independence in low-burden TD) and sustained bitopertin PPIX reductions in EPP at EHA 2026. The company confirmed a Type A meeting with FDA where APOLLO Phase 3 data, due Q4 2026, can serve as basis for a CRL response and potentially support traditional approval. Initial DISC-3405 data in polycythemia vera also expected Q4 2026.
Key Facts
- Phase 2 RALLY-MF: 55% of nTD patients achieved hemoglobin increase ≥1.5 g/dL for ≥12 weeks (major response)
- 64% of TD Low and 50% of TD High MF patients achieved transfusion independence over 12-16 weeks
- 56% of JAK inhibitor-concomitant patients achieved major hematologic response across transfusion groups
- HELIOS OLE: Sustained PPIX reductions and improved light tolerance with up to 2.5+ years bitopertin exposure
- Type A meeting confirmed APOLLO Phase 3 readout in Q4 2026 can serve as basis for CRL response and potentially support traditional approval
- RESTORE-PV Phase 2 initial data for DISC-3405 in polycythemia vera expected Q4 2026, third program could enter pivotal development in 2027
- DISC-0974 well-tolerated; diarrhea was only related AE in ≥2 subjects, majority of AEs not related
Financial Impact
Disc Medicine has no revenue or earnings yet. The catalyst-rich H2 2026 hinges on APOLLO bitopertin Phase 3, which can potentially resolve the existing CRL and unlock a traditional approval for EPP (an orphan indication with no approved therapies), value-driving for a $2.6B market cap biotech entirely dependent on pipeline success.
Risk Factors
- APOLLO Phase 3 failure would be severely bearish, bitopertin is the most advanced asset and a CRL is already outstanding; a miss could eliminate path-to-approval
- CRL on CMC or safety/efficacy grounds if APOLLO data are not clean + additional manufacturing/resolution risk before re-submission
- Clinical-stage biotech with no revenue, any pipeline setback (DISC-0974 regulatory delay, DISC-3405 early data miss) would erode premium valuation
- Broader biotech sentiment or financing risk, Disc may require equity raises to fund three programs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311034 |
Track record
43 reports on IRON
6 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +20.07% at T+20 after the Sep 3, 2026 report. 10 of 15 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $87.08 Now $76.59 −12.05% settles Dec 10
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $78.91 Now $76.59 +2.94% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Bullish 7/10 Entry $78.47 Now $76.59 −2.40% settles Dec 4
- Nov 4, 202612d ago Press Release Neutral 3/10 Entry $83.28 Now $76.59 −8.03% settles Dec 3
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $81.16 Now $76.59 −5.63% settles Dec 2
- Oct 26, 202621d ago SC 13D/A Neutral 3/10 Entry $79.90 Now $76.59 −4.14% settles Nov 24
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $74.51 Now $76.59 −2.79% settles Nov 20
- Oct 21, 202626d ago 424B5 Bearish 6/10 Entry $75.03 Now $76.59 −2.08% settles Nov 19
- Oct 21, 202626d ago 144 Neutral 2/10 Entry $75.03 Now $76.59 +2.08% settles Nov 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers